"Antiviral Agents" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Agents used in the prophylaxis or therapy of VIRUS DISEASES. Some of the ways they may act include preventing viral replication by inhibiting viral DNA polymerase; binding to specific cell-surface receptors and inhibiting viral penetration or uncoating; inhibiting viral protein synthesis; or blocking late stages of virus assembly.
| Descriptor ID |
D000998
|
| MeSH Number(s) |
D27.505.954.122.388
|
| Concept/Terms |
Antiviral Agents- Antiviral Agents
- Agents, Antiviral
- Antivirals
- Antiviral Drugs
- Drugs, Antiviral
|
Below are MeSH descriptors whose meaning is more general than "Antiviral Agents".
Below are MeSH descriptors whose meaning is more specific than "Antiviral Agents".
This graph shows the total number of publications written about "Antiviral Agents" by people in this website by year, and whether "Antiviral Agents" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1995 | 1 | 0 | 1 |
| 1996 | 1 | 0 | 1 |
| 1997 | 2 | 0 | 2 |
| 1998 | 1 | 0 | 1 |
| 2000 | 1 | 1 | 2 |
| 2002 | 2 | 1 | 3 |
| 2003 | 1 | 2 | 3 |
| 2004 | 3 | 1 | 4 |
| 2005 | 2 | 2 | 4 |
| 2006 | 2 | 1 | 3 |
| 2007 | 1 | 0 | 1 |
| 2008 | 3 | 0 | 3 |
| 2009 | 2 | 1 | 3 |
| 2010 | 4 | 0 | 4 |
| 2011 | 5 | 3 | 8 |
| 2012 | 5 | 0 | 5 |
| 2013 | 1 | 1 | 2 |
| 2014 | 2 | 2 | 4 |
| 2015 | 2 | 2 | 4 |
| 2016 | 5 | 4 | 9 |
| 2017 | 5 | 1 | 6 |
| 2018 | 1 | 1 | 2 |
| 2019 | 4 | 2 | 6 |
| 2020 | 4 | 4 | 8 |
| 2021 | 3 | 6 | 9 |
| 2022 | 0 | 6 | 6 |
| 2023 | 1 | 9 | 10 |
| 2024 | 1 | 1 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "Antiviral Agents" by people in Profiles.
-
VanKoten HW, Pence BC, Klinkenberg JR, Das S, Patterson SE. Synthesis and evaluation of anti-Giardia activity of oseltamivir analogs. Bioorg Med Chem Lett. 2025 Feb 01; 116:130035.
-
Travis JK, Costantini LM. Inhibiting KSHV replication by targeting the essential activities of KSHV processivity protein, PF-8. J Med Virol. 2024 Oct; 96(10):e29958.
-
DeBarros K, Khan M, Coleman M, Bond VC, Floyd V, Gbodossou E, Diop A, Krumpe LRH, O'Keefe BR, Powell MD. MoMo30 Binds to SARS-CoV-2 Spike Variants and Blocks Infection by SARS-CoV-2 Pseudovirus. Viruses. 2024 Sep 07; 16(9).
-
Metibemu DS, Adeyinka OS, Falode J, Hampton T, Crown O, Ojobor JC, Narayanan A, Julander J, Ogungbe IV. Inhibitor of the non-structural protein 2 protease shows promising efficacy in mouse models of chikungunya. Eur J Med Chem. 2024 Nov 15; 278:116808.
-
Metibemu DS, Adeyinka OS, Falode J, Crown O, Ogungbe IV. Inhibitors of the Structural and Nonstructural Proteins of Alphaviruses. ACS Infect Dis. 2024 Aug 09; 10(8):2507-2524.
-
Holmes J, Islam SM, Milligan KA. Exploring Cannabinoids as Potential Inhibitors of SARS-CoV-2 Papain-like Protease: Insights from Computational Analysis and Molecular Dynamics Simulations. Viruses. 2024 May 30; 16(6).
-
Persaud KE, Sahu RR, Neary MC, Kapdi AR, Lakshman MK. Two short approaches to the COVID-19 drug ?-D-N4-hydroxycytidine and its prodrug molnupiravir. Org Biomol Chem. 2024 01 24; 22(4):735-740.
-
Havranek B, Demissie R, Lee H, Lan S, Zhang H, Sarafianos S, Ayitou AJ, Islam SM. Discovery of Nirmatrelvir Resistance Mutations in SARS-CoV-2 3CLpro: A Computational-Experimental Approach. J Chem Inf Model. 2023 11 27; 63(22):7180-7188.
-
Sutar Y, Singh SK, Dhoble S, Mali J, Adams J, Yadavalli T, Date AA, Shukla D. Oral Self-Nanoemulsifying System Containing Ionic Liquid of BX795 Is Effective against Genital HSV-2 Infection in Mice. ACS Infect Dis. 2024 01 12; 10(1):93-106.
-
Gandhi MM, Nguyen KL, Lake JE, Liao D, Khodabakhshian A, Guerrero M, Shufelt CL, Bairey Merz CN, Jordan WC, Daar ES, Bhattacharya D, Chew KW. Proprotein convertase subtisilin/kexin 9 levels decline with hepatitis C virus therapy in people with HIV/hepatitis C virus and correlate with inflammation. AIDS. 2024 03 01; 38(3):317-327.